ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
A Multicentre Phase 2b Trial to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC), Suitable for Treatment With a Taxane
Sponsor: Modra Pharmaceuticals
This PHASE2 trial investigates Castration-resistant Prostate Cancer and Prostate Cancer Metastatic and is currently completed. Modra Pharmaceuticals leads this study, which shows 9 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2022 — May 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Nov 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Modra Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barnaul, Russia , Budapest, Hungary , Chelyabinsk, Russia , Debrecen, Hungary , Detroit, United States , Győr, Hungary , Göttingen, Germany , Konin, Poland , Krasnoyarsk, Russia , Las Vegas, United States and 15 more locations